Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals Chief HR Officer Gregg Russo reported equity compensation activity. On February 17, 2026, 687 restricted stock units vested and converted into an equal number of common shares at $0.00 per share. Of these, 211 shares were withheld to cover taxes, leaving 476 shares delivered. The derivative award vests in five equal annual tranches each February 13 from 2026 through 2030, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals, Inc. reported that it will present at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026. The company has made its conference slide presentation available as Exhibit 99.1 to this report and incorporates it by reference. The disclosure is furnished under Regulation FD, meaning it is not treated as filed for liability purposes or automatically included in other securities law filings. The company also highlights that the report and presentation contain forward-looking statements and directs readers to its Form 10-K for the year ended December 31, 2024 and subsequent SEC reports for a discussion of risks that could cause actual results to differ.
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported equity compensation activity. On January 5, 2026, 42,105 restricted stock units vested and were converted into an equal number of Catalyst common shares at a price of $0 per share. According to the filing, this award vests in five equal annual tranches from January 1, 2025 through January 1, 2029.
To cover withholding taxes tied to the vesting, the company withheld 10,577 common shares, leaving Daly with 271,266 common shares directly owned after the transactions. He also reported 2,618,539 restricted stock units beneficially owned following this vesting event.
Catalyst Pharmaceuticals director Molly Harper reported exercising stock options and selling common shares of the company. On 12/12/2025, she exercised options to purchase 20,000 shares of common stock at an exercise price of $5.78 per share, converting them into common shares. She then sold common stock in several open-market transactions, including 15,527 shares at a weighted average price of $23.198, 4,473 shares at $23.734, and 6,746 shares at $23.06 per share. Following these transactions, she directly beneficially owned 2,360 shares of common stock and 128,497 options to purchase common stock. The sales were made on the open market for personal reasons and to help fund the option exercise, and were not due to any disagreement with the company.
Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts. On 12/01/2025, he made bona-fide gifts of common stock, par value $0.001 per share, recorded at a price of $0 per share, classified under transaction code "G" for gifts. After the reported transactions, he directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock. The explanation notes that the gifts were to irrevocable trusts for family members who do not share his household, and he is not a trustee and has no direct or indirect influence over the trusts' investment decisions.
Catalyst Pharmaceuticals (CPRX) reported equity transactions by its Chief Strategy Officer on a Form 4. On 11/21/2025, the officer acquired 5,603 shares of common stock through the exercise of derivative awards and had 1,364 shares withheld to cover taxes, leaving 45,320 shares of common stock owned directly.
The filing also shows new derivative awards dated 11/20/2025, including options to purchase 106,873 shares of common stock at an exercise price of $22.77 per share and 32,257 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual tranches from November 20, 2026 through November 20, 2028. Additional RSUs that vest in thirds each year from November 21, 2025 to November 21, 2027 are also reported.
Catalyst Pharmaceuticals (CPRX) reported insider equity activity by its Chief Operating and Scientific Officer on a Form 4. On November 20, 2025, the officer received options to purchase 158,454 shares of common stock at an exercise price of $22.77 per share. These options vest in three equal installments on November 20, 2026, November 20, 2027, and November 20, 2028.
Also on November 20, 2025, the officer was granted 47,826 restricted stock units (RSUs), with shares delivered upon vesting. A separate RSU award vests in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027, and shares must be delivered within sixty days of each vesting date; the first tranche of 8,267 shares was delivered on November 21, 2025. Following these transactions, the officer directly owned 1,067,930 shares of common stock.
Catalyst Pharmaceuticals (CPRX) reported an equity compensation grant to its Chief HR Officer on November 20, 2025. The officer received options to purchase 20,531 shares of common stock at an exercise price of $22.77 per share, along with 6,197 restricted stock units (RSUs). The options vest in three equal annual installments, with one-third vesting on November 20, 2026, one-third on November 20, 2027, and one-third on November 20, 2028. Each RSU represents a right to receive one share of common stock upon vesting, and shares will be delivered to the officer when the RSUs vest. Following these awards, the officer beneficially owns 66,276 options and 72,473 RSUs in total.
Catalyst Pharmaceuticals (CPRX) reported insider equity awards for a director on a Form 4. On November 20, 2025, the reporting person received options to purchase 18,115 shares of common stock at an exercise price of $22.77, and 5,468 restricted stock units (RSUs). On November 21, 2025, 947 RSUs were settled in common stock, increasing the director’s directly held common shares to 2,360.
Following these transactions, the director held 116,555 stock options, 121,076 RSUs, and 2,360 shares of common stock, all directly. The options and RSUs generally vest in three equal annual tranches on specified dates in 2025, 2026, 2027, and 2028, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals Executive Vice President and CFO Michael W. Kalb reported equity award activity in company stock. On 11/21/2025, he acquired 6,894 shares of common stock through an option exercise (code M) and had 2,485 shares withheld to cover taxes on vesting (code F), leaving him with 8,606 shares of common stock held directly.
He was granted options to purchase 131,536 shares at an exercise price of $22.77 per share, expiring on 11/20/2032. These options vest in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028. He also received 39,701 restricted stock units, which convert into common shares upon vesting, and additional RSU-related vesting of 6,894 shares scheduled in equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.